• Product NameNFκB-p65(Phospho-Ser276) Antibody
• Host SpeciesRabbit
• ClonalityPolyclonal
• PurificationAntibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy using non-phosphopeptide.
• ApplicationsWB;IHC;IF;IP
• Species ReactivityHu Ms Rt
• SpecificityThe antibody detects endogenous level of NFκB-p65 only when phosphorylated at serine 276.
• Immunogen TypePeptide-KLH
• Immunogen Description: Peptide sequence around phosphorylation site of serine 276(R-P-S(p)-D-R) derived from Human NFκB-p65.
• Target NameNFκB-p65
• ModificationPhospho
• Alternative Names    p65, NFKB3
• Accession No. Swiss-Prot#:Q04206 NCBI Gene#:5970 NCBI Protein#:NP_001138610.1
• UniprotQ04206
• Gene ID5970;
• SDS-PAGE MW 65KD
• Concentration 1.0mg/ml
• Formulation Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
• Storage Store at -20 ˚C/1 year

• WB 1:500 - 1:2000. IHC 1:100 - 1:300 Immunoprecipitation: 2-5 ug:mg lysate IF 1:50-200

   

 NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and p65-c-Rel complexes are transcriptional activators. The NF-kappa-B p65-p65 complex appears to be involved in invasin-mediated activation of IL-8 expression. The inhibitory effect of I-kappa-B upon NF-kappa-B the cytoplasm is exerted primarily through the interaction with p65. p65 shows a weak DNA-binding site which could contribute directly to DNA binding in the NF-kappa-B complex. Associates with chromatin at the NF-kappa-B promoter region via association with DDX1.

• Immunofluorescence staining of methanol-fixed Hela cells using NFκB-p65 (Phospho-Ser276) Antibody #11011.
• Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using NFκB-p65 (Phospho-Ser276) Antibody #11011 (left) or the same antibody preincubated with blocking peptide #51011 (right).
• Immunohistochemical analysis of paraffin- embedded human breast carcinoma tissue using NFκB-p65 (Phospho-Ser276) antibody #11011.
• Immunohistochemical analysis of paraffin- embedded human lung carcinoma tissue using NFκB-p65 (Phospho-Ser276) antibody #11011.
• Immunofluorescence staining of methanol-fixed MEF cells untreated or treated with TNF using NFκB-p65 (Phospho-Ser276) Antibody #11011.
• Western Blot analysis of various cells using Phospho-NFκB-p65 (S276) Polyclonal Antibody diluted at 1:1000

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting